Cover Image
市場調查報告書

癌症分析及途徑:技術及全球市場

Cancer Profiling and Pathways: Technologies and Global Markets

出版商 BCC Research 商品編碼 133421
出版日期 內容資訊 英文 362 Pages
訂單完成後即時交付
價格
Back to Top
癌症分析及途徑:技術及全球市場 Cancer Profiling and Pathways: Technologies and Global Markets
出版日期: 2014年01月13日 內容資訊: 英文 362 Pages
簡介

癌症分析技術的全球市場,2012年達到了261億美元的規模。這個市場2013年為近301億美元,之後以年複合成長率12.8%成長,預計2018年達到548億美元。

本報告提供全球癌症分析技術市場相關分析、現在及未來的癌症分析技術及手法的概要與分析彙整、市場上主要產品、企業及競爭環境的概括,以及研究開發主要的課題及問題點等,為您概述為以下內容。

第1章 簡介:序

  • 調查的目標和目的
  • 調查實施理由
  • 調查範圍
  • 主要讀者
  • 調查手法
  • 資訊來源
  • 關於作者
  • 相關報告
  • BCC線上服務
  • 免除責任

第2章 摘要

第3章 概要

  • 癌症分析
  • 生物標記
  • 指南
  • 癌症的早期發現和診斷
  • 途徑分析
  • 分子分析
  • 歷史的事實
  • 癌症分析
  • 分子分析的臨床性效用
  • 分子分析手法
  • 癌症分析:未來的目標

第4章 目前分析技術

  • 基因學
  • DNA定序(序列測定)
  • 定序技術,市場及用途

第5章 表觀基因剖析

  • 表觀基因形勢的概要與簡介
  • 癌症的應用
  • DNA甲基化
  • 微小RNA
  • 微小RNA的專利及展望
  • 表觀遺傳(後成的)治療的發展
  • 主要企業

第6章 蛋白質體學

  • 蛋白質體學和蛋白質分析
  • 蛋白質體學蛋白質分析手法
  • 技術
  • 癌症研究的蛋白質體學技術的應用
  • 技術及規定
  • 蛋白質體學及倡議
  • 癌症的應用
  • 癌症治療的蛋白質體學
  • 蛋白質體學的臨床性應用
  • 分析的軟體
  • 治療、診斷企業
  • 使用蛋白質體學的診斷產品
  • 蛋白質體學研究中心

第7章 醣質學

  • 醣質學是什麼?
  • 醣質學和專利

第8章 代謝體學

  • 代謝體學是什麼?
    • 技術
    • 檢測手法

第9章 生物資訊學,資料庫及途徑分析

  • 微陣列資料庫

第10章 癌症分析與臨床性發展

  • NODALITY
  • ROSETTA CANCER TESTING SERVICES
  • IRIS BIOTECHNOLOGIES
  • 乳癌:表示流程的3個觀點
  • 個體化醫療方面課題
  • 基因分析樣品
  • 基因健康商務的發展

第11章 市場

  • 全球DNA診斷市場
  • 癌症診斷市場
  • 癌症生物標記實驗市場
  • SNP遺傳基因型決策、分析市場
  • 微陣列市場
  • 生物晶片/實驗室晶片(LOAC)市場
  • 市場動態
  • DNA定序市場
  • PCR市場

第12章 企業簡介

第13章 癌症分析:專利形勢和最新的動向

  • MIRNA THERAPEUTICS
  • TROVAGENE
  • 哥倫比亞大學有關DNA定序專利控告ILLUMINA
  • 在主要的致癌基因型決策研究中記錄第5,000個腫瘤簡介

第14章 參考資料

第15章 引用文獻

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO073B

The global market for cancer profiling technologies reached $26.1 billion in 2012. This market is expected to grow to nearly $30.1 billion in 2013 and $54.8 billion in 2018, a compound annual growth rate (CAGR) of 12.8% over the five-year period, 2013 to 2018.

This report provides:

  • An overview of the global market for cancer profiling and biomarker studies
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  • Discussion of products in this market, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market
  • Examination of evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, which are integral to deciphering the molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers
  • Identifications of important cancer profiling techniques, market share by type of products on the market and market share by company, as well as types of cancers and biomarkers
  • Coverage of epigenetic, methylation, and miRNA products in development, products in clinical trials, and currently marketed and clinical-stage development products
  • Comprehensive company profiles of key players in the market.

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report, BIO073B: Cancer Profiling and Pathways: Technologies and Global Markets, provides a detailed overview and thorough analysis and insight of the present and future cancer profiling and pathways. This report analyzes in detail the cancer profiling and tools markets. This report includes products in this market, and detailed analyses of markets and competitive environments, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market. The report includes information about significant products, key players, issues and trends, current market status of cancer profiling methods, strengths, weaknesses, opportunities and challenges, major issues involved in the research and development (R&D) of more effective cancer profiling techniques, and new cancer therapeutics in development and in clinical trials.

REASONS FOR DOING THE STUDY

Gene expression profiling methods enable the detection and measurement of multiple expressed gene transcripts in a single RNA sample. Continually evolving methods, such as microarray analysis, multiplex PCR and quantitative real-time PCR, are integral to deciphering the molecular mechanisms involved in gene function, biological development and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers. Life Technologies, Agilent and Affymetrix, respectively, are maintaining their leads in the quantitative real-time PCR and microarray market segments. Understanding the multivariate nature of cancer and drug response also depends on molecular profiling at epigenetic, genetic and protein levels. A major challenge is to develop an understanding of this multivariate dysregulation, with respect both to how it arises from diverse genetic mutations and to how it may be ameliorated by prospective treatments. High-throughput experimental platform technologies ranging from genomic sequencing to transcriptomic, proteomic and metabolomic profiling are now commonly used for molecular-level characterization of tumor cells and surrounding tissues. The increasing use of biomarkers in clinical services is boosting the overall biomarker service market.

SCOPE OF REPORT

Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size and competitive landscape, a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments is needed. Microarray technologies provide analysis of tens of thousands of molecules for a variety of assays, including drug binding, molecular interactions, enzyme activity and pathway identification. These microarrays, which include DNA microarrays, protein microarrays, tissue microarrays, low complexity microarrays and carbohydrate microarrays, are excellent tools for gene expression profiling, biomarker profiling and diagnostics.

Pharmaceutical and biotechnology researchers use microarrays to streamline drug target identification, selection, validation and predictive testing. Rapid growth in the clinical research and diagnostic devices markets holds great potential for applications of microarray technology, including basic research, clinical trials and diagnostic devices. This report examines various microarray platforms and the technologies that are utilized to detect DNA and proteins for the purpose of drug discovery, disease diagnosis and disease monitoring. This report also examines companies that are actively developing and marketing microarray instrumentation or microarray biochips.

The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players and competitive outlook. This report will also provide market tables and also provides company profiles.

This report analyzes the cancer profiling and pathways market: technologies market, tools market, and application market (diagnosis, drug development and discovery). This report also looks into recent studies, microRNA detection and profiling, clinically oriented microRNA profiling in several human cancers. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. Relationship between miRNAs and epigenetics is also examined. This report categorizes the market for epigenetics, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. This report also looks at SNPs analysis instruments, reagents, software and services, providing information critical to understanding the business behind this new technology.

The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.

INTENDED AUDIENCE

This report is an exhaustive study on the cancer profiling and pathways, giving crucial statistics and analysis on the market structure, market size, key technologies and segments, important trends in technology development, next-generation technologies, major opportunities and market shares of key players and innovative drugs. This report may prove crucial for the firms or investors seeking investments in the concerned sector. As market needs change with progress, the value of the information provided from microarrays, sequencing and qRT-PCR has become more interesting for markets outside of basic life-science research. In oncology-expression pattern profiling, comparing expression in normal and cancer tissues shows an unexpected greater reliability in classifying cancer types than the signatures of protein-coding genes. Researchers have also successfully classified poorly differentiated tumors using expression profiles. Along with their diagnostic potential, cancer-profiling techniques have also reportedly proven to be of prognostic value to predict survival among cancer patients and poor responsiveness to adjuvant chemotherapy and other drugs.

Table of Contents

CHAPTER 1 INTRODUCTION 2

  • STUDY GOALS AND OBJECTIVES 2
  • REASONS FOR DOING THE STUDY 2
  • SCOPE OF REPORT 2
  • INTENDED AUDIENCE 3
  • METHODOLOGY 4
  • INFORMATION SOURCES 4
  • ABOUT THE AUTHOR 4
  • RELATED BCC RESEARCH REPORTS 5
  • BCC RESEARCH ONLINE SERVICES 5
  • DISCLAIMER 5

CHAPTER 2 SUMMARY 7

  • CANCER PROFILING AND PATHWAYS 7
  • SUMMARY TABLE MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2018 ($ MILLIONS) 9
  • SUMMARY FIGURE MARKET FOR CANCER PROFILING TECHNOLOGIES, 2012-2018 ($ MILLIONS) 9

CHAPTER 3 OVERVIEW 11

  • CANCER PROFILING 11
  • BIOMARKERS 11
  • GUIDELINES 11
    • SCREENING TESTS 12
  • EARLY DETECTION AND DIAGNOSIS OF CANCER 12
  • PATHWAY PROFILING 13
    • LINKING CANCER DISEASE THROUGH PATHWAY PROFILING 13
  • MOLECULAR PROFILING 13
  • HISTORICAL FACTS 14
    • MOLECULAR PROFILES 14
    • ONCOTYPE DX 15
  • CANCER PROFILING 15
    • CHALLENGES 16
    • PRIMARY OBJECTIVES OF THE MINDACT TRIAL 18
    • Lung Cancer 19
    • Challenges 19
  • CLINICAL UTILITY OF MOLECULAR PROFILING 20
    • CARIS LIFE SCIENCES 21
      • Head and Neck Cancer Data 22
      • Pathological Classification 22
  • MOLECULAR PROFILING APPROACHES 23
  • TABLE 1 DIFFERENT TOOLS FOR MOLECULAR PROFILING OF CANCER 24
  • CANCER PROFILING: FUTURE GOALS 25

CHAPTER 4 CURRENT PROFILING TECHNIQUES 27

  • GENOMICS 27
  • TABLE 2 GENOMICS: TECHNOLOGIES 27
  • TABLE 3 THE APPLICATIONS MARKET 28
  • TABLE 4 THE SEGMENT TYPES 28
    • GENOMIC PROFILING 28
    • TABLE 5 LIST OF TECHNIQUES/TOOLS FOR GENOMIC PROFILING 30
    • TABLE 6 GENOMIC REVENUE AND FORECAST, THROUGH 2018 ($ MILLIONS) 32
    • FIGURE 1 GENOMIC REVENUE AND FORECAST, 2012-2018 ($ MILLIONS) 32
      • Challenges and Market Trends 32
    • MICROARRAYS 33
    • TABLE 7 COMMONLY USED DNA MICROARRAYS 34
      • Oligonucleotide Microarrays 34
      • Spotted Microarrays 35
      • Microarrays Fabrication 35
    • MICROARRAYS: LIMITATIONS 36
    • MICROARRAYS AND APPLICATIONS 37
    • COMPARATIVE GENOMIC HYBRIDIZATION (CGH) 37
      • Method 38
    • ARRAY COMPARATIVE GENOME HYBRIDIZATION 38
      • Applications of Array-CGH 40
    • CGH AND CANCER 41
      • Array CGH and Neuroblastoma 41
    • KEY COMPANIES 42
    • TABLE 8 SELECTED COMPANIES WITH MICROARRAY TECHNOLOGIES 42
    • KEY PLAYERS 42
      • Genomic Profiling - Array Labeling and Genotyping 44
    • MICROARRAYS TO CLINICAL PROBLEMS 45
    • SINGLE NUCLEOTIDE POLYMORPHISM (SNP) 45
    • TABLE 9 KEY COMPANIES 46
    • MULTI-COLOR FISH 46
      • Spectral Karyotyping 46
    • COMPANIES 47
  • DNA SEQUENCING 47
    • EMERGING DNA SEQUENCING TECHNOLOGIES 48
      • Fluorescent in situ Sequencing (FISSEQ) 48
      • Pyrosequencing 48
      • Massively Parallel Signature Sequencing (MPSS) 48
      • Single-Molecule Sequencing 49
      • Bacterial Artificial Chromosome (BAC)-end Sequencing 49
    • HIGH-THROUGHPUT SEQUENCING 49
      • In vitro Clonal Amplification 49
      • Parallelized Sequencing 50
      • Sequencing by Ligation 50
      • Microfluidic Sanger Sequencing 50
    • OTHER SEQUENCING TECHNOLOGIES 50
    • APPLICATIONS TO CANCER 51
  • SEQUENCING TECHNOLOGIES, MARKET AND THEIR APPLICATIONS 52
    • NEXT-GEN SEQUENCING SERVICES 52
    • TABLE 10 COMPANIES WITH SEQUENCING TECHNOLOGIES 53
      • Key Companies 53
      • TABLE 11 NEXT-GEN SEQUENCING COMPANIES 53
    • THE NEXT NEXT-GENERATION COMPANIES 54
      • Roche 454 Pyrosequencing 54
      • Illumina NGS Sequencing 54
      • Ion Torrent NGS Sequencing 55
      • Applications of NGS Sequencing 55
    • LATEST DEVELOPMENTS 55
      • Complete Genomics 56
      • Nanopore Sequencing 56
      • Genia 56
    • GENOME SEQUENCING 57
    • PATENTS AND SEQUENCING 58
    • TABLE 12 SEQUENCING PATENTS AWARDED 58
  • SUMMARY 59
    • NEXT-GENERATION SEQUENCING TECHNOLOGIES 59
    • NEXT-GENERATION SEQUENCING: FUTURE 60
    • GENOMICS AND CANCER-SOME EXAMPLES 60
    • TABLE 13 MUTATIONS IDENTIFIED IN CANCER 61
    • MUTATIONS PREDICTING RESISTANCE TO TARGETED THERAPIES 62
    • SEQUENCING AND THE CLINIC 62
    • TABLE 14 CONSORTIUM LISTED RESPONSIBILITIES 63
    • TRANSCRIPTOMIC PROFILING 65
    • TABLE 15 TRANCRIPTOMIC TECHNIQUES 65
    • MICROARRAY-BASED GENE EXPRESSION PROFILING 66
      • Serial Analysis of Gene Expression (SAGE) 68
      • mRNA 68
      • Data Analysis and Design 69
    • TILING ARRAYS 70
    • QRT-PCR 71
    • APPLICATIONS TO CANCER 71
    • EMERGING MICROARRAY TECHNOLOGIES 72
    • MICROARRAY PATENTS 72
    • FUTURE 73

CHAPTER 5 EPIGENOMIC PROFILING 75

  • OVERVIEW AND INTRODUCTION TO THE EPIGENETICS LANDSCAPE 75
    • APPLICATIONS TO CANCER 75
    • DNA METHYLATION 76
      • Covalent Histone Modifications 77
      • Histone Modifications in Cancer 80
    • MICRORNA 81
      • MicroRNA Technologies: Impact on Diagnostics and Therapeutics 82
    • TABLE 16 MIRNA AND SIRNA-A COMPARISON 83
      • MicroRNA Expression 83
    • EPIGENETIC CHANGES AND CANCER STEM CELLS 84
    • EPIGENETIC THERAPY OF CANCER 85
    • TABLE 17 EPIGENETIC DRUGS APPROVED BY THE U.S. FDA 87
    • TABLE 18 HDAC DRUGS 88
    • LEADING EPIGENETIC COMPANIES 89
    • TABLE 19 SELECTED EPIGENETIC COMPANIES 90
    • EPIGENETICS AND MICRORNA PROFILING-FINDING PATHWAYS TO
    • TREATMENT 91
    • TABLE 20 CURRENTLY USED MICRORNA TECHNIQUES 92
      • Human Cancer and Epigenetic Regulation of miRNAs 93
    • TABLE 21 MICRORNA EXPRESSION IN CANCER 94
    • TABLE 22 EPI-MIRNAS REGULATING EFFECTORS OF THE EPIGENETIC MACHINERY 95
    • MICRORNAS AND THERAPEUTIC APPLICATIONS IN CANCER 95
    • POLYMORPHISMS IN MICRORNAS ASSOCIATED WITH CANCER RISK 97
      • MICRORNAS AS PROGNOSTIC AND THERAPEUTIC BIOMARKERS 98
      • microRNA as Therapeutic Targets 98
      • Computational Methods for Analysis of Cellular Functions and Pathways 99
    • TABLE 23 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN COLON CANCER 101
    • ANTI-CANCER DRUGS AND MICRORNA TARGETS 102
    • TABLE 24 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN PANCREATIC CANCER 103
    • CASE STUDY: EPIGENETIC SILENCING OF THE INTRONIC MICRORNA MIR-342 IN COLORECTAL CANCER 106
    • TABLE 25 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN CRC AND NORMAL COLORECTAL TISSUE 107
    • TABLE 26 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN NORMAL COLON AND EARLY-STAGE COLORECTAL CANCER (STAGES I AND II) 108
    • TABLE 27 MIRNAS DIFFERENTIALLY EXPRESSED IN EARLY- (I AND II) VS LATE-STAGE (III AND IV) DISEASE 109
    • TABLE 28 PATHWAYS TARGETED BY CRC MIRNAS 109
    • DIAGNOSTIC AND THERAPEUTIC MICRORNA STRATEGIES IN CANCER 110
    • TABLE 29 MICRORNAS AS PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS: POTENTIAL EFFECT ON BREAST CANCER MANAGEMENT 113
    • THERAPEUTIC POTENTIAL 114
    • TABLE 30 MICRORNAS (MIRS) WITH ALTERED EXPRESSION IN OVARIAN CARCINOMA 116
      • Challenges and Future 118
    • THERAPEUTIC STRATEGIES 118
      • Implications for Cancer 120
    • MICRORNAS IN DISEASE DIAGNOSTICS 120
    • CIRCULATING MICRORNAS 120
    • MICRORNA PROFILING METHODS 121
    • CLINICAL MICRORNA DIAGNOSTICS 121
      • Nucleotide Polymorphism in Diagnostics 122
    • MICRORNAS IN THERAPEUTICS 122
    • TABLE 31 MICRORNA-BASED THERAPEUTICS: DEVELOPMENT STATUS 123
      • Miravirsen (Santaris Pharma) 124
      • Regulus Therapeutics 124
      • TABLE 32 SELECTED MICRORNAS IN DEVELOPMENT AND CANCER 125
      • Mirna Therapeutics 125
      • miRagen Therapeutics 126
    • MICRORNA PATENTS AND OUTLOOK 127
      • Regulus, Alnylam, and Isis Announce U.S. Allowance of Tuschl III
      • Patent Application Covering miR-21 127
      • TABLE 33 MICRORNA PATENTS 128
    • FUTURE 129
    • TABLE 34 MICRORNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 130
    • FIGURE 2 MICRORNA MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 130
    • TABLE 35 SELECTED COMPANIES FOR MIRNA-SPECIFIC TOOLS AND REAGENTS 131
    • METHYLATION MARKERS 132
    • DNA METHYLATION, AN EPIGENETIC PROCESS 132
    • CURRENT METHODS AND PRODUCTS 133
      • Cancer-Specific Methylation Biomarkers 135
    • CLINICAL IMPLICATIONS 136
    • TABLE 36 INTRINSIC CLASSIFICATION OF BREAST CANCER BY GENE EXPRESSION PROFILES AND CELL SURFACE HORMONAL EXPRESSION 137
      • Clinical Testing 138
      • Blood-Based Tests 139
    • FUTURE DIRECTIONS 139
    • TABLE 37 SELECT EPIGENETIC-BASED DIAGNOSTIC COMPANIES 140
    • EPIGENETIC DIAGNOSTIC DEVELOPMENT 141
    • TABLE 38 SELECTED METHYLATION TESTS FOR CANCER 142
    • EPIGENETIC DRUGS 142
    • HDAC INHIBITORS 143
      • Novel HDIs on Trial 144
        • Celleron 145
        • Acetylon Pharmaceuticals 145
        • Syndax 146
        • TABLE 39 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 147
        • FIGURE 3 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 147
    • EPIGENETIC THERAPEUTIC DEVELOPMENT 147
    • TABLE 40 EPIGENETIC DRUGS FOR CANCER-APPROVED/LATE-STAGE CLINICAL TRIALS 148
      • Latest Developments 148
        • September 11, 2013 148
        • August 27, 2013 149
        • December 18, 2012 149
        • September 13, 2012 149
        • Pracinostat 149
      • MEI Pharma 150
      • S*BIO 150
      • Panobinostat 150
    • KEY PLAYERS 151
      • CellCentric 151
      • Epigenomics 151
      • Constellation Pharmaceuticals 152
      • Epizyme 152
      • Abbott 152
      • Veridex 153
      • OncoMethylome Sciences 153
      • TABLE 41 METHYLATION MARKERS IN DEVELOPMENT 154
      • Quest Diagnostics 154
      • TABLE 42 SELECTED COMPANIES WITH METHYLATION PRODUCTS 155
      • Orion Genomics 155
      • Zymo Research 157
      • BioChain 157
      • EpigenDx 157
      • Rubicon Genomics 158
      • SeqWright 158
      • Qiagen 159
      • TABLE 43 METHYLATION MARKERS/TESTS-PATENTS 160
      • EXACT Sciences Corporation 160
      • Activemotif 161
      • Clinical Implications 163
      • OncoMethylome Sciences-GST-Pi/APC Methylation Test for Detection of Prostate Cancer 163
        • MDxHealth 165
        • Summary 165

CHAPTER 6 PROTEOMICS 167

  • PROTEOMICS AND PROTEIN PROFILING 167
    • PROTEOMICS PROTEIN PROFILING APPROACHES 168
    • TECHNIQUES 170
    • TABLE 44 BIOMARKER INDENTIFIED USING TWO-DIMENSIONAL ELECTROPHORESIS (2-DE) 170
    • TABLE 45 BIOMARKER INDENTIFIED USING MASS SPECTROSCOPY (MS) 171
    • APPLICATIONS OF PROTEOMIC TECHNIQUES IN CANCER RESEARCH 173
    • TECHNOLOGIES AND LIMITATIONS 174
    • PROTEOMICS AND INITIATIVES 175
    • APPLICATIONS TO CANCER 176
    • PROTEOMICS IN THE TREATMENT OF CANCER 178
    • CLINICAL APPLICATIONS OF PROTEOMICS 180
      • Lung Cancer 180
      • Ovarian Cancer 181
      • Prostate Cancer 183
      • Breast Cancer 184
    • PROTEOMIC APPROACHES IN THERAPEUTIC TARGETS 185
    • KEY PLAYERS 187
      • Kreatech Biotechnology 187
      • Thermo Fisher Scientific 187
      • GE Healthcare 187
      • ProteinOne 188
      • Waters 188
      • PerkinElmer 189
      • Protneteomix 189
      • Whatman 189
      • Arrayit Corporation 190
      • Qiagen 190
      • TABLE 46 ANTIBODY ARRAY VENDORS 191
    • ANALYTICAL SOFTWARE 192
    • THERAPEUTIC AND DIAGNOSTIC COMPANIES 193
    • PROTEOMICS-BASED DIAGNOSTIC PRODUCTS 195
      • Myriad Genetics 195
      • NextGen Sciences 195
      • ProFACT Proteomics 195
      • Proteologics 196
      • Proteome Factory 196
      • ProteomTech 197
      • Pharmaceutical Candidates 197
      • Quattromed 198
      • Sense Proteomic Limited 198
      • SomaLogic 198
      • Structural Bioinformatics (SBI) 198
      • WITA Proteomics 199
      • Zyomyx 199
    • PROTEOMIC RESEARCH CENTERS 200
      • Stanford University: Molecular Therapeutics Program 200
      • Vanderbilt University-Mass Spectrometry Research Center (MSRC) 200
    • CLINICAL TRIAL USING PROTEOMICS TECHNOLOGIES FOR PERSONALIZED MEDICINE 202
    • PROTEOMICS AND MEDICINE 203
    • PROTEOMICS MARKET 203
    • TABLE 47 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, THROUGH 2018 ($ MILLIONS) 203
    • FIGURE 4 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, 2012-2018 ($ MILLIONS) 204
      • Applied Proteomics 204

CHAPTER 7 GLYCOMICS 207

  • WHAT IS GLYCOMICS? 207
    • TECHNIQUES 207
    • ANALYTICAL HIGH-THROUGHPUT TECHNOLOGIES 209
    • EMERGENCE OF GLYCOARRAYS 209
    • GLYCOINFORMATICS 210
    • BIOMEDICAL APPLICATIONS 210
    • GLYCOMICS'S RELATIONSHIP WITH OTHER "OMICS" TECHNOLOGIES 211
    • GLYCOMICS FOR BIOMARKER DISCOVERY 212
    • TABLE 48 THE SEVEN TUMOR GLYCOME LABORATORIES 212
    • CANCER AND GLYCOMICS 213
      • Glycomics-Biomarkers for Ovarian Cancer 213
      • TABLE 49 CLINICAL TRIALS AND GLYCOMICS 214
    • GLYCOMICS AND PATENTS 215
      • Carbohydrate Encapsulated Nanoparticles 215
      • Glycosylated Specificity Exchangers (Tripep) 215
      • Glycosylated Specificity Exchangers (Tripep) 215
      • Tripep AB/ChronTech Pharma AB 215
      • TABLE 50 GLYCOMICS PATENTS 216
      • Serum Marker for Measuring Liver Fibrosis 216
      • Recent Advances 217

CHAPTER 8 METABOLOMICS 219

  • WHAT IS METABOLOMICS? 219
    • METABOLOME 219
      • Techniques 220
      • Detection Methods 221
    • METABOLOMICS AND DRUG DISCOVERY 222
    • BIOMARKER IDENTIFICATION 222

CHAPTER 9 BIOINFORMATICS, DATABASES AND PATHWAY ANALYSIS 225

  • MICROARRAY DATABASE 225
  • TABLE 51 SOME OF THE MOST KNOWN PUBLIC, CURATED MICROARRAY DATABASES 226

CHAPTER 10 CANCER PROFILING AND CLINICAL DEVELOPMENT 231

  • NODALITY 231
  • ROSETTA CANCER TESTING SERVICES 232
  • IRIS BIOTECHNOLOGIES 232
  • IN BREAST CANCER-THREE PERSPECTIVES ILLUSTRATING CURRENT
  • CHALLENGES IN PERSONALIZED MEDICINE 233
    • BIOMARKERS 235
    • DIAGNOSTIC TESTS IN DEVELOPMENT 235
    • TABLE 52 DIAGNOSTIC TESTS IN DEVELOPMENT 235
    • APPROVED TESTS 236
      • Affymetrix 236
      • Agendia 236
      • TABLE 53 APPROVED DIAGNOSTIC TESTS 237
    • GENOMIC ASSAYS 238
    • TABLE 54 CURRENT LEADERS IN THE GENOMIC MARKET 239
    • GENOMIC HEALTH BUSINESS PROGRESS 239
    • TABLE 55 ONCOTYPE DX SALES AND FORECAST, 2010-2012 ($ MILLIONS) 239
      • MammaPrint Assay 239
    • CANCER AND BIOMARKERS 240
    • TABLE 56 KEY PREDICTIVE BIOMARKERS FOR TRASTUZUMAB THERAPY 242
    • TABLE 57 PREDICTIVE BIOMARKERS FOR EGFR TKI THERAPIES IN LUNG CANCER 244
    • FUTURE DIRECTIONS 248
    • TABLE 58 PREDICTIVE BIOMARKERS FOR ANTI-EGFR ANTIBODY THERAPIES IN
    • COLORECTAL CANCER 249

CHAPTER 11 MARKET 252

  • GLOBAL DNA DIAGNOSTICS MARKET 252
  • TABLE 59 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, THROUGH 2018 ($
  • MILLIONS) 252
  • FIGURE 5 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, 2012-2018 ($ MILLIONS) 252
  • THE CANCER DIAGNOSTICS MARKET 253
    • CANCER DIAGNOSTIC TESTS 253
  • THE CANCER/TUMOR PROFILING MARKET 253
  • TABLE 60 CANCER PROFILING MARKET: SEGMENT TYPES 254
  • TABLE 61 GLOBAL CANCER PROFILING MARKET AND FORECAST, THROUGH 2018
  • ($ MILLIONS) 254
  • TABLE 62 CANCER PROFILING MARKET: APPLICATIONS 255
  • TABLE 63 CANCER PROFILING MARKET: TECHNOLOGIES 255
    • PERSONALIZED MEDICINE 255
  • CANCER BIOMARKER TESTING MARKET 256
  • TABLE 64 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($
  • MILLIONS) 257
  • FIGURE 6 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 257
  • TABLE 65 THE KEY PLAYERS 258
  • TABLE 66 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 258
  • FIGURE 7 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 258
    • CANCER BIOMARKER TESTS 259
    • CANCER DISEASE MANAGEMENT 259
    • GENOMICS MARKET 260
      • Trends 261
      • TABLE 67 GENOMICS MARKET REVENUE AND FORECAST, THROUGH 2018 ($ MILLIONS) 261
      • FIGURE 8 GENOMICS MARKET REVENUE AND FORECAST, 2012-2018 ($ MILLIONS) 261
  • SNP GENOTYPING AND ANALYSIS MARKET 262
  • TABLE 68 SNP GENOTYPING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 262
  • FIGURE 9 SNP GENOTYPING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 263
    • MICROARRAY MARKET 263
    • TABLE 69 GLOBAL BIOCHIPS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 264
    • FIGURE 10 GLOBAL BIOCHIPS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 264
    • TABLE 70 GLOBAL BIOCHIPS MARKET SHARE (%) 265
    • TABLE 71 MICROARRAY MARKETS 266
      • Key Microarray Companies 266
      • Microarray Use 267
      • TABLE 72 MICROARRAYS: MODALITIES 267
      • Global Microarray Market 268
      • TABLE 73 GLOBAL MICROARRAY MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 268
      • FIGURE 11 GLOBAL MICROARRAY MARKET FORECAST 2012-2018 ($ MILLIONS) 268
      • TABLE 74 MICROARRAY MARKET SHARE, 2012 (%) 269
    • BIOCHIP/LAB-ON-A-CHIP (LOAC) MARKET 269
    • TABLE 75 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 270
    • FIGURE 12 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, 2010-2018 ($ MILLIONS) 270
    • DIAGNOSTIC MICROARRAYS 270
    • TABLE 76 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 271
    • FIGURE 13 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 271
    • TABLE 77 SOME COMMERCIALLY AVAILABLE CANCER DIAGNOSTIC DEVICES BASED ON MICROARRAY TECHNOLOGY 272
      • In Situ Hybridization Diagnostic Arrays 272
      • TABLE 78 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 272
      • FIGURE 14 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 272
      • Microarray Market Growth 273
      • TABLE 79 MICROARRAY TECHNOLOGIES: KEY COMPANIES AND PRODUCTS 274
      • DNA Microarrays 275
      • FIGURE 15 GLOBAL MICROARRAY MARKET FORECAST, 2012-2018 ($ MILLIONS) 276
    • MARKET DYNAMICS 276
    • KEY PLAYERS 277
      • Affymetrix 277
        • Recent Developments 277
        • TABLE 81 AFFYMETRIX UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (THOUSANDS) 278
      • Agilent Technologies 278
      • TABLE 82 AGILENT TECHNOLOGIES NET REVENUE, 2012 ($ MILLIONS) 278
        • Product Sales 279
        • TABLE 83 GENE EXPRESSION PRODUCTS: MARKET SHARE COMPANIES, 2012 (%) 279
        • Strategic Alliances and Acquisitions 280
        • Historical Trends and Future 281
        • TABLE 84 MICROARRAY PRODUCTS 281
      • Illumina 281
      • Pacific Biosciences 282
      • Arrayit Corporation 282
      • TABLE 85 ARRAYIT PATENTS 283
        • Arrayit Products 283
        • TABLE 86 ARRAYIT CORPORATION REVENUE, BY FISCAL QUARTER, 2011-2013 ($) 284
        • Arrayit's Future 285
      • Roche 285
      • PerkinElmer 286
      • Boreal Genomics 286
    • DNA SEQUENCING MARKET 286
      • First-Generation DNA Sequencing 286
      • NEXT-GENERATION SEQUENCING SYSTEMS 287
      • A NEW GENERATION OF DNA SEQUENCING 287
    • DNA SEQUENCING AND PERSONALIZED MEDICINE 288
    • TABLE 87 SEQUENCING-SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 289
    • FIGURE 16 SEQUENCING-SALES AND FORECAST, 2012-2018 ($ MILLIONS) 289
    • TABLE 88 THE NEXT-GENERATION SEQUENCING (NGS) MARKET: PLATFORMS 290
    • HISTORY 290
    • TABLE 89 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2011-2013 292
    • NEXT-GENERATION SEQUENCING INSTRUMENT INDUSTRY 293
    • TABLE 90 NEXT-GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%) 294
    • TABLE 91 NEXT-GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%) 295
    • NEXT-GENERATION SEQUENCING TARGET ENRICHMENT INDUSTRY 296
    • TABLE 92 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY COMPANY PLATFORM METHOD 296
    • TABLE 93 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS 298
      • Developments 298
      • Roche 299
      • Illumina 299
      • TABLE 94 ILLUMINA REVENUE AND FORECAST, 2012-2015 ($ MILLIONS) 300
      • TABLE 95 ILLUMINA NEW DEVELOPMENTS 300
      • TABLE 96 ILLUMINA PRODUCT AND SERVICE REVENUE AND FORECAST, 2012-2015 ($ MILLIONS) 301
      • TABLE 97 ILLUMINA-REVENUE, 2008-2010 ($ MILLIONS) 302
      • FIGURE 17 ILLUMINA-REVENUE, 2008-2010 ($ MILLIONS) 302
      • TABLE 98 SELECTED COMPANIES AND SEQUENCING PRODUCTS 303
    • MARKET SHARE 303
      • Oxford Nanopore 304
      • Life Technologies 304
      • TABLE 99 LIFE TECHNOLOGIES REVENUES, 2008-2010 ($ MILLIONS) 305
      • FIGURE 18 LIFE TECHNOLOGIES REVENUES, 2008-2010 ($ MILLIONS) 305
    • PCR MARKET 307
    • TABLE 100 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 307
    • FIGURE 19 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 307
    • TABLE 101 KEY PCR COMPANIES 308
    • TABLE 102 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 309
    • FIGURE 20 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 309
    • REAL-TIME PCR MARKET 309
    • TABLE 103 REAL-TIME (QRTPCR) PCR SELECTED COMPANIES 310
    • TABLE 104 REAL-TIME (QRT-PCR) MARKET, THROUGH 2018 ($ MILLIONS) 311
    • FIGURE 21 REAL-TIME (QRT-PCR) MARKET, 2012-2018 ($ MILLIONS) 311
    • EPIGENETICS AND MARKET 312
    • TABLE 105 GLOBAL EPIGENETIC MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 313
    • FIGURE 22 GLOBAL EPIGENETIC MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 314
    • TABLE 106 EPIGENETIC MARKET: KEY PLAYERS 314
    • TABLE 107 EPIGENETICS ARRAYS AND SELECTED CANCER PROFILING COMPANIES 315
    • EPIGENETIC THERAPEUTICS 316
    • TABLE 108 DRUGS APPROVED BY THE FDA AND COMMERCIALLY AVAILABLE 316
    • FUTURE: EPIGENETIC THERAPIES 317
    • TABLE 109 EPIGENETICS AND SELECTED COMPANIES 318
    • EPIGENETICS AND DIAGNOSTIC TESTS 319
    • TABLE 110 EPIGENETIC DIAGNOSTIC TESTS 319
    • MIRNA MARKET 319
    • TABLE 111 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 320
    • FIGURE 23 TOTAL MIRNA MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 321
    • TABLE 112 TOTAL MIRNA MARKET INCLUDING SALES, 2008 (%) 322
    • EPIGENETICS AND CANCER MARKET AND FUTURE GROWTH 322
    • TABLE 113 SELECTED COMPANIES WITH METHYLATION PRODUCTS 323
    • CURRENT USE OF PROTEOMICS IN THE PHARMA INDUSTRY 323
    • TABLE 114 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, THROUGH 2018 ($ MILLIONS) 323
    • FIGURE 24 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, 2012-2018 ($ MILLIONS) 323
    • TABLE 115 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 324
    • FIGURE 25 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 324
    • PROTEIN MICROARRAYS AND TRENDS 325
    • THE METABOLOMICS MARKET 326
    • FUTURE 328
    • CONCLUSION 329
    • TABLE 116 SELECTED COMPANIES OFFERING, DEVELOPING OR PARTNERING TO DEVELOP COMPANION DIAGNOSTICS 329

CHAPTER 12 COMPANY PROFILES 332

  • KEY PLAYERS 332
    • ABBOTT LABORATORIES 332
    • AFFYMETRIX 332
    • AGENDIA 333
    • AGILENT TECHNOLOGIES 334
    • ARRAYIT 334
    • ASTRAZENECA PLC. 335
    • ASURAGEN, INC. 335
    • BOREAL GENOMICS 336
    • CARIS LIFE SCIENCES 336
    • CLARINET 336
    • DAKO 337
    • EISAI INC. (HEADQUARTERS) 337
    • ENDOTIS PHARMA 338
    • EPPENDORF BIOCHIP SYSTEMS 338
    • EXIQON, INC 338
    • GENOMIC HEALTH 339
    • GLAXOSMITHKLINE 339
    • GLYCOMINDS LIMITED 339
    • GP BIOSCIENCES 340
    • IKARYOS DIAGNOSTICS 340
    • ILLUMINA 341
    • LIFE TECHNOLOGIES 341
    • LIPOMICS TECHNOLOGIES 341
    • MERCK 342
    • METABOLON 342
    • MIRAGEN THERAPEUTICS 342
    • MIRNA THERAPEUTICS INC. 343
    • OXFORD GENE TECHNOLOGY 343
    • Oxford Nanopore Technologies 343
    • PACIFIC BIOSCIENCES 344
    • PERKINELMER 344
    • PFIZER 345
    • PROTEOME SCIENCES 345
    • RAYBIOTECH 345
    • REGULUS THERAPEUTICS 346
    • ROCHE 346
    • RUBICON GENOMICS 346
    • TABLE 117 MICROARRAY COMPANIES 347

CHAPTER 13 CANCER PROFILING: PATENT LANDSCAPE AND LATEST DEVELOPMENTS 350

  • TABLE 118 PATENT APPLICATIONS IN MICROARRAYS 351
  • MIRNA THERAPEUTICS 354
  • TROVAGENE 355
  • TABLE 119 COMPANIES DEVELOPING MIRNA-RELATED TECHNOLOGIES 356
    • COLUMBIA UNIVERSITY SUES ILLUMINA OVER DNA SEQUENCING PATENTS 357
    • MAJOR CANCER GENOTYPING STUDY LOGS 5,000TH TUMOR PROFILE 358
      • Developing a Cancer-Specific Microarray 359
      • Oxford Nanopore Announces $64 Million Fundraising 359
      • Silicon Peptide Chips Could Transform Diagnostics 359
      • Agilent Technologies Introduces HaloPlex Exome Kits and SureCall Software 360
    • PROTEOME SCIENCES 361
    • CONCLUSIONS 362

CHAPTER 14 REFERENCES 364

CHAPTER 15 CITED REFERNCES 368

  • CITED REFERNCES 368

LIST OF TABLES

  • SUMMARY TABLE MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2018 ($ MILLIONS) 9
  • TABLE 1 DIFFERENT TOOLS FOR MOLECULAR PROFILING OF CANCER 24
  • TABLE 2 GENOMICS: TECHNOLOGIES 27
  • TABLE 3 THE APPLICATIONS MARKET 28
  • TABLE 4 THE SEGMENT TYPES 28
  • TABLE 5 LIST OF TECHNIQUES/TOOLS FOR GENOMIC PROFILING 30
  • TABLE 6 GENOMIC REVENUE AND FORECAST, THROUGH 2018 ($ MILLIONS) 32
  • TABLE 7 COMMONLY USED DNA MICROARRAYS 34
  • TABLE 8 SELECTED COMPANIES WITH MICROARRAY TECHNOLOGIES 42
  • TABLE 9 KEY COMPANIES 46
  • TABLE 10 COMPANIES WITH SEQUENCING TECHNOLOGIES 53
  • TABLE 11 NEXT-GEN SEQUENCING COMPANIES 53
  • TABLE 12 SEQUENCING PATENTS AWARDED 58
  • TABLE 13 MUTATIONS IDENTIFIED IN CANCER 61
  • TABLE 14 CONSORTIUM LISTED RESPONSIBILITIES 63
  • TABLE 15 TRANCRIPTOMIC TECHNIQUES 65
  • TABLE 16 MIRNA AND SIRNA-A COMPARISON 83
  • TABLE 17 EPIGENETIC DRUGS APPROVED BY THE U.S. FDA 87
  • TABLE 18 HDAC DRUGS 88
  • TABLE 19 SELECTED EPIGENETIC COMPANIES 90
  • TABLE 20 CURRENTLY USED MICRORNA TECHNIQUES 92
  • TABLE 21 MICRORNA EXPRESSION IN CANCER 94
  • TABLE 22 EPI-MIRNAS REGULATING EFFECTORS OF THE EPIGENETIC MACHINERY 95
  • TABLE 23 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN COLON CANCER 101
  • TABLE 24 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN PANCREATIC CANCER 103
  • TABLE 25 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN CRC AND NORMAL COLORECTAL TISSUE 107
  • TABLE 26 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN NORMAL COLON AND EARLY-STAGE COLORECTAL CANCER (STAGES I AND II) 108
  • TABLE 27 MIRNAS DIFFERENTIALLY EXPRESSED IN EARLY- (I AND II) VS LATE-STAGE (III AND IV) DISEASE 109
  • TABLE 28 PATHWAYS TARGETED BY CRC MIRNAS 109
  • TABLE 29 MICRORNAS AS PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS: POTENTIAL EFFECT ON BREAST CANCER MANAGEMENT 113
  • TABLE 30 MICRORNAS (MIRS) WITH ALTERED EXPRESSION IN OVARIAN CARCINOMA 116
  • TABLE 31 MICRORNA-BASED THERAPEUTICS: DEVELOPMENT STATUS 123
  • TABLE 32 SELECTED MICRORNAS IN DEVELOPMENT AND CANCER 125
  • TABLE 33 MICRORNA PATENTS 128
  • TABLE 34 MICRORNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 130
  • TABLE 35 SELECTED COMPANIES FOR MIRNA-SPECIFIC TOOLS AND REAGENTS 131
  • TABLE 36 INTRINSIC CLASSIFICATION OF BREAST CANCER BY GENE EXPRESSION PROFILES AND CELL SURFACE HORMONAL EXPRESSION 137
  • TABLE 37 SELECT EPIGENETIC-BASED DIAGNOSTIC COMPANIES 140
  • TABLE 38 SELECTED METHYLATION TESTS FOR CANCER 142
  • TABLE 39 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 147
  • TABLE 40 EPIGENETIC DRUGS FOR CANCER-APPROVED/LATE-STAGE CLINICAL TRIALS 148
  • TABLE 41 METHYLATION MARKERS IN DEVELOPMENT 154
  • TABLE 42 SELECTED COMPANIES WITH METHYLATION PRODUCTS 155
  • TABLE 43 METHYLATION MARKERS/TESTS-PATENTS 160
  • TABLE 44 BIOMARKER INDENTIFIED USING TWO-DIMENSIONAL ELECTROPHORESIS (2-DE) 170
  • TABLE 45 BIOMARKER INDENTIFIED USING MASS SPECTROSCOPY (MS) 171
  • TABLE 46 ANTIBODY ARRAY VENDORS 191
  • TABLE 47 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, THROUGH 2018 ($ MILLIONS) 203
  • TABLE 48 THE SEVEN TUMOR GLYCOME LABORATORIES 212
  • TABLE 49 CLINICAL TRIALS AND GLYCOMICS 214
  • TABLE 50 GLYCOMICS PATENTS 216
  • TABLE 51 SOME OF THE MOST KNOWN PUBLIC, CURATED MICROARRAY DATABASES 226
  • TABLE 52 DIAGNOSTIC TESTS IN DEVELOPMENT 235
  • TABLE 53 APPROVED DIAGNOSTIC TESTS 237
  • TABLE 54 CURRENT LEADERS IN THE GENOMIC MARKET 239
  • TABLE 55 ONCOTYPE DX SALES AND FORECAST, 2010-2012 ($ MILLIONS) 239
  • TABLE 56 KEY PREDICTIVE BIOMARKERS FOR TRASTUZUMAB THERAPY 242
  • TABLE 57 PREDICTIVE BIOMARKERS FOR EGFR TKI THERAPIES IN LUNG CANCER 244
  • TABLE 58 PREDICTIVE BIOMARKERS FOR ANTI-EGFR ANTIBODY THERAPIES IN COLORECTAL CANCER 249
  • TABLE 59 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 252
  • TABLE 60 CANCER PROFILING MARKET: SEGMENT TYPES 254
  • TABLE 61 GLOBAL CANCER PROFILING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 254
  • TABLE 62 CANCER PROFILING MARKET: APPLICATIONS 255
  • TABLE 63 CANCER PROFILING MARKET: TECHNOLOGIES 255
  • TABLE 64 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 257
  • TABLE 65 THE KEY PLAYERS 258
  • TABLE 66 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 258
  • TABLE 67 GENOMICS MARKET REVENUE AND FORECAST, THROUGH 2018 ($ MILLIONS) 261
  • TABLE 68 SNP GENOTYPING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 262
  • TABLE 69 GLOBAL BIOCHIPS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 264
  • TABLE 70 GLOBAL BIOCHIPS MARKET SHARE (%) 265
  • TABLE 71 MICROARRAY MARKETS 266
  • TABLE 72 MICROARRAYS: MODALITIES 267
  • TABLE 73 GLOBAL MICROARRAY MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 268
  • TABLE 74 MICROARRAY MARKET SHARE, 2012 (%) 269
  • TABLE 75 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 270
  • TABLE 76 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 271
  • TABLE 77 SOME COMMERCIALLY AVAILABLE CANCER DIAGNOSTIC DEVICES BASED ON MICROARRAY TECHNOLOGY 272
  • TABLE 78 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 272
  • TABLE 79 MICROARRAY TECHNOLOGIES: KEY COMPANIES AND PRODUCTS 274
  • TABLE 81 AFFYMETRIX UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (THOUSANDS) 278
  • TABLE 82 AGILENT TECHNOLOGIES NET REVENUE, 2012 ($ MILLIONS) 278
  • TABLE 83 GENE EXPRESSION PRODUCTS: MARKET SHARE COMPANIES, 2012 (%) 279
  • TABLE 84 MICROARRAY PRODUCTS 281
  • TABLE 85 ARRAYIT PATENTS 283
  • TABLE 86 ARRAYIT CORPORATION REVENUE, BY FISCAL QUARTER, 2011-2013 ($) 284
  • TABLE 87 SEQUENCING-SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 289
  • TABLE 88 THE NEXT-GENERATION SEQUENCING (NGS) MARKET: PLATFORMS 290
  • TABLE 89 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2011-2013 292
  • TABLE 90 NEXT-GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%) 294
  • TABLE 91 NEXT-GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%) 295
  • TABLE 92 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY COMPANY PLATFORM METHOD 296
  • TABLE 93 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS 298
  • TABLE 94 ILLUMINA REVENUE AND FORECAST, 2012-2015 ($ MILLIONS) 300
  • TABLE 95 ILLUMINA NEW DEVELOPMENTS 300
  • TABLE 96 ILLUMINA PRODUCT AND SERVICE REVENUE AND FORECAST, 2012-2015 ($ MILLIONS) 301
  • TABLE 97 ILLUMINA-REVENUE, 2008-2010 ($ MILLIONS) 302
  • TABLE 98 SELECTED COMPANIES AND SEQUENCING PRODUCTS 303
  • TABLE 99 LIFE TECHNOLOGIES REVENUES, 2008-2010 ($ MILLIONS) 305
  • TABLE 100 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 307
  • TABLE 101 KEY PCR COMPANIES 308
  • TABLE 102 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 309
  • TABLE 103 REAL-TIME (QRTPCR) PCR SELECTED COMPANIES 310
  • TABLE 104 REAL-TIME (QRT-PCR) MARKET, THROUGH 2018 ($ MILLIONS) 311
  • TABLE 105 GLOBAL EPIGENETIC MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 313
  • TABLE 106 EPIGENETIC MARKET: KEY PLAYERS 314
  • TABLE 107 EPIGENETICS ARRAYS AND SELECTED CANCER PROFILING COMPANIES 315
  • TABLE 108 DRUGS APPROVED BY THE FDA AND COMMERCIALLY AVAILABLE 316
  • TABLE 109 EPIGENETICS AND SELECTED COMPANIES 318
  • TABLE 110 EPIGENETIC DIAGNOSTIC TESTS 319
  • TABLE 111 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 320
  • TABLE 112 TOTAL MIRNA MARKET INCLUDING SALES, 2008 (%) 322
  • TABLE 113 SELECTED COMPANIES WITH METHYLATION PRODUCTS 323
  • TABLE 114 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, THROUGH 2018 ($ MILLIONS) 323
  • TABLE 115 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 324
  • TABLE 116 SELECTED COMPANIES OFFERING, DEVELOPING OR PARTNERING TO DEVELOP COMPANION DIAGNOSTICS 329
  • TABLE 117 MICROARRAY COMPANIES 347
  • TABLE 118 PATENT APPLICATIONS IN MICROARRAYS 351
  • TABLE 119 COMPANIES DEVELOPING MIRNA-RELATED TECHNOLOGIES 356

LIST OF FIGURES

  • SUMMARY FIGURE MARKET FOR CANCER PROFILING TECHNOLOGIES, 2012-2018 ($ MILLIONS) 9
  • FIGURE 1 GENOMIC REVENUE AND FORECAST, 2012-2018 ($ MILLIONS) 32
  • FIGURE 2 MICRORNA MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 130
  • FIGURE 3 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 147
  • FIGURE 4 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, 2012-2018 ($ MILLIONS) 204
  • FIGURE 5 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, 2012-2018 ($ MILLIONS) 252
  • FIGURE 6 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 257
  • FIGURE 7 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 258
  • FIGURE 8 GENOMICS MARKET REVENUE AND FORECAST, 2012-2018 ($ MILLIONS) 261
  • FIGURE 9 SNP GENOTYPING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 263
  • FIGURE 10 GLOBAL BIOCHIPS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 264
  • FIGURE 11 GLOBAL MICROARRAY MARKET FORECAST 2012-2018 ($ MILLIONS) 268
  • FIGURE 12 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, 2010-2018 ($ MILLIONS) 270
  • FIGURE 13 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 271
  • FIGURE 14 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 272
  • FIGURE 15 GLOBAL MICROARRAY MARKET FORECAST, 2012-2018 ($ MILLIONS) 276
  • FIGURE 16 SEQUENCING-SALES AND FORECAST, 2012-2018 ($ MILLIONS) 289
  • FIGURE 17 ILLUMINA-REVENUE, 2008-2010 ($ MILLIONS) 302
  • FIGURE 18 LIFE TECHNOLOGIES REVENUES, 2008-2010 ($ MILLIONS) 305
  • FIGURE 19 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 307
  • FIGURE 20 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 309
  • FIGURE 21 REAL-TIME (QRT-PCR) MARKET, 2012-2018 ($ MILLIONS) 311
  • FIGURE 22 GLOBAL EPIGENETIC MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 314
  • FIGURE 23 TOTAL MIRNA MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 321
  • FIGURE 24 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, 2012-2018 ($ MILLIONS) 323
  • FIGURE 25 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 324
Back to Top